An 82-year-old widowed woman with a history of recurrent unipolar major depression is referred to the electroconvulsive therapy (ECT) service of an academic medical center. During her illness, she has had four episodes of major depression consisting of periods of depressed mood, crying spells, loss of interest in usual activities, insomnia, loss of appetite and weight, difficulty with concentration, feelings of helplessness and hopelessness, and thoughts of suicide. During the current episode, which has lasted for 6 months, she has had typical symptoms of melancholic depression, as well as psychotic symptoms (e.g., a somatic delusion that she has terminal cancer), with suicidal ideation and a plan for taking a drug overdose. Previous treatment during this episode has included citalopram (Celexa), duloxetine (Cymbalta), and the combination of olanzepine (Zyprexa) and duloxetine, but the patient did not have a response to any of these agents. She could not tolerate the anticholinergic side effects of tricyclic antidepressants. Her psychiatrist seeks specialty consultation regarding the appropriateness and safety of ECT for this patient.
Depression is a complex and heterogeneous dis order that comprises three broad domains of clin ical manifestations: disorders of mood, cognitive function, and neurovegetative functions (i.e., en ergy, sleep, appetite, and sexual function). The cause of depression is likewise thought to be com plex, including various genetic, developmental, and environmental factors.
Most models of the pathophysiology of de pression implicate dysregulation in corticolim bic circuits affecting regional brain structure and function, neurotransmitter function, and neuro endocrine regulation. Researchers have described structural abnormalities in the hippocampus (where atrophy is correlated with the duration of depression in days), the subgenual prefrontal cor tex (where atrophy is associated with familial de pression), and whitematter hyperintensities 7, [10] [11] [12] [13] [14] [15] (notably in depression in the elderly). Functional abnormalities in the prefrontal, temporal, pari etal, limbic, paralimbic, striatal, and thalamic regions have been identified. Abnormalities in neurotransmitter function and receptor expres sion have been described, including presynaptic and postsynaptic abnormalities in serotoninrecep tor expression and deficiencies in γaminobutyric acid (GABA). Data from neuroendocrine challenge studies (e.g., the dexamethasone suppression test) have provided evidence of impaired negative feed back inhibition in the hypothalamic-pituitaryadrenal axis, resulting in hypercortisolemia, which itself can cause further impairment in brain function.
The pathophysiology of depression in late life appears to have some unique features. Suscepti bility to depression in older adults is thought to be in part mediated by frontal-striatal-limbic dysfunction caused by vascular, neurochemical, neurodegenerative, and agingrelated factors. 16 The "vascular depression hypothesis" 7-9 posits that vascular lesions in white matter disrupt key pathways, leading to a "disconnection syndrome" with abnormal functional activation in down stream cortical and limbic regions and resulting in impaired mood regulation, cognition, and neurovegetative function. A "depression-execu tive dysfunction syndrome" has been described in latelife depression; this syndrome is character ized by impaired executive function, compromised integrity of the prefrontal white matter, 17 dysfunc tion in frontolimbic circuits, and a poor response to antidepressant medications. 8, 11, [18] [19] [20] [21] [22] [23] ECT for the treatment of depression and other psychiatric disorders involves the application of electricity to the scalp in order to induce seizure activity. This form of therapy has a range of ef fects on the neurobiologic features of depression. ECT increases cortical GABA concentrations 24 and enhances serotonergic function. 25, 26 It also affects the hypothalamic-pituitary-adrenal axis, normalizing the results of the dexamethasone suppression test. Functional brain activation is altered. 27 Neuronal structure and synaptic plas ticity also appear to be influenced; animal stud ies have shown increases in neurotropic factors and cell proliferation. 28
CL INIC A L E V IDENCE
ECT has been reported to result in a prompt im provement in symptoms of depression in the ma jority of patients treated. The Consortium for Research in ECT (CORE) reported a 75% remis sion rate among 217 patients who completed a short course of ECT during an acute episode of depression, with 65% of patients having remission by the fourth week of therapy. 29 A systematic re view of six trials involving 256 patients by the UK [United Kingdom] ECT Review Group, reported in 2003, showed that the effect size for ECT was 0.91 (significantly more effective than sham ECT), and a review of 18 trials involving 1144 patients showed that the effect size for ECT was 0.80 (more effective than pharmacotherapy). 30 These data have shortcomings, including suboptimal dosing and an inadequate description of the drug treatment.
A metaanalysis showed ECT to be more ef fective than antidepressant medications alone in treating the psychotic subtype of depression, and it showed a trend for ECT to be better than com bination pharmacotherapy. 31 In a study involving 253 patients, the CORE group reported that pa tients with the psychotic subtype of depression had higher rates of response to ECT than patients without psychosis 32 ; this study also showed that response rates were higher among the elderly. 33 The efficacy of ECT is highly dependent on technique, with remission rates ranging from 20% to more than 80%, depending on how the treatment is performed. Doubleblind, random ized, controlled trials have shown powerful inter actions between electrode placement and dosage (relative to seizure threshold) in the efficacy and side effects of ECT. 34 In a review of 22 trials involving 1408 patients, the UK ECT Review Group reported that bilateral electrode placement was moderately more effective than right unilat eral placement (effect size, 0.32), 30 but the effi cacy of right unilateral ECT is dosesensitive, and several of the trials in this analysis may have used insufficient doses. Several studies have not shown a difference in efficacy between highdose right unilateral ECT and bilateral ECT, and these stud ies have indicated that unilateral electrode place ment on the right side is associated with a lower incidence of cognitive side effects, especially at longterm followup. 34, 35 One report suggests success rates of 30 to 47% for ECT in community hospitals. These rates have been less robust than those in clinical trials. 36 This discrepancy is related in part to coexisting conditions, but it may also be related to the ten dency to discontinue ECT prematurely, often in order to mitigate side effects. In this study, treat ing psychiatrists often discontinued ECT before complete remission was achieved. 36 
CL INIC A L USE
ECT was first introduced as a treatment for psy chiatric disorders in the 1930s. Early experience with the treatment raised concerns about serious side effects, including fractures (before the use of neuromuscular blocking agents) and cognitive impairment (in part related to dose and tech nique). 37 With the introduction of pharmacologic therapy for depression and the concerns about the adverse effects of ECT, the use of ECT de clined. In recent decades, however, further re search and methodologic advances have led to re newed interest in the role of ECT for the treatment of patients with depression.
The second edition of the guidelines of the American Psychiatric Association (APA) Task Force on Electroconvulsive Therapy, which was pub lished in 2001, includes a complete description of the current clinical use of ECT. 38 Briefly, the pri mary indications for ECT among patients with depression are lack of a response to or intolerance of antidepressant medications, a good response to previous ECT, and the need for a rapid and definitive response (e.g., because of psychosis or a risk of suicide). ECT can be used in both uni polar and bipolar disorders.
The decision to use ECT depends on several factors, including the severity and chronicity of the patient's depression, the likelihood that alter native treatments would be effective, the patient's preference, and a weighing of the risks and ben efits. Although ECT is more effective than anti depressant medications, it is typically reserved for use after several medication trials because of its relatively higher risk of side effects.
There are no absolute contraindications to ECT, but factors that have been associated with reduced efficacy include a prolonged episode, lack of re sponse to medication, and coexisting psychiatric diagnoses such as a personality disorder. 36 Per sons with unstable cardiac disease such as ische mia or arrhythmias, cerebrovascular disease such as recent cerebral hemorrhage or stroke, or in creased intracranial pressure may be at increased risk for complications. The preECT workup there fore should include a complete medical and neurologic evaluation to detect and manage such conditions. ECT can be used safely in elderly pa tients and in persons with cardiac pacemakers or implantable cardioverter-defibrillators. 39 ECT can also be used safely during pregnancy, with proper precautions and in consultation with an obste trician.
Common electrode positions include bilateral, right unilateral, and bifrontal (Fig. 1) . Right uni lateral and bifrontal placement may be selected to reduce the burden of side effects, whereas bilat eral placement may be selected if the right uni lateral or bifrontal positions are unlikely to be effective (e.g., in patients in whom previous ECT treatment with the latter positions has failed).
The ECT dose is measured in millicoulombs of charge delivered; the dose administered must be sufficient to induce seizure activity. One ap proach, called seizurethreshold titration, involves giving progressively higher doses during the ini tial ECT session until the seizure threshold is reached, and then selecting a dose at various percentages above the seizure threshold during subsequent treatment sessions. Another accepted approach involves the use of an agebased dosing algorithm, although this technique has some lim itations, since age accounts for only a small per centage of the variance in the seizure threshold. 40 Some medications (e.g., lithium, theophylline, and medications with anticonvulsant action) can interact with ECT, and they should be tapered or discontinued before ECT is initiated. Antidepres sant drugs are often discontinued before the ini tiation of ECT. However, clinical experience sug gests that at least some of these agents may be used safely during treatment, and such an ap proach may reduce the risk of a relapse of de pression after treatment is completed. ECT is performed while the patient is under general anesthesia; therefore, all patients must undergo a full evaluation by an anesthesiologist, including an assessment of the risk associated with anesthesia, before the start of ECT. 41 Pa tients are not typically intubated, but mask ven tilation with supplemental oxygen is used. Neuro muscular blocking agents are administered to prevent skeletal muscle contraction and possible injury during tonic-clonic activity. Atropine or glycopyrrolate may be given to minimize brady cardia and salivation.
The electroencephalogram is monitored dur ing ECT to confirm seizure activity and to docu ment seizure duration. In addition, evidence of seizure motor activity is monitored. This tech nique involves the placement of a tourniquet around one of the patient's ankles before the administration of the muscle relaxant so that the potential for muscle contraction in the foot is maintained. Oxygen saturation and cardiac rhythm are monitored during the procedure.
In the United States, ECT treatments are usu ally administered three times weekly for approxi mately 6 to 12 treatments, depending on the severity of the patient's symptoms and the rapid ity of the response. Since premature discontinu ation of ECT can predispose the patient to relapse, it is important to monitor the efficacy of the treat ment in a systematic fashion. Efficacy can be monitored by using standardized rating scales for depression or by keeping track of the severity of selected target symptoms. It is also essential to track side effects that emerge during treatment, such as amnesia, with the use of rating scales of cognitive performance and memory.
After remission, it is important to initiate main tenance therapy with an antidepressant and a mood stabilizer, and in some patients, mainte nance ECT is required. The optimal approach to maintenance with ECT or medications requires further study.
ECT can be performed on an inpatient or an outpatient basis. The APA has estimated the cost of ECT to be approximately $800 to $1,000 for each treatment in a series; this cost includes the The three standard electrode placements are bifrontotemporal (commonly referred to as "bilateral"), right unilateral, and bifrontal. In bilateral placement, there is one electrode on each side of the head. In right unilateral placement, one electrode is in the right frontotemporal position, and the second electrode is placed to the right of the vertex. In bifrontal placement, there is one electrode on each side of the head, but the placement is more frontal than it is in standard bilateral placement. professional fees of the psychiatrist and the an esthesiologist, as well as the cost of the use of the facility, equipment, and supplies. 42
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A DV ER SE EFFEC T S
In the short term, ECT causes anterograde amne sia that typically resolves soon after ECT is com pleted. In addition, postictal disorientation or even delirium may occur, but these conditions also tend to resolve within 1 hour after the pro cedure. Prolonged seizures during ECT are rare.
Retrograde amnesia is the most common per sistent adverse effect of ECT. Shortly after ECT, most patients have gaps in the memory of events that occurred before the treatment, and retro grade amnesia may extend back several months or years. The memory of autobiographical infor mation is less affected by ECT than the memory of events of an impersonal nature. 43 Although retrograde amnesia often improves during the first few months after ECT, for many patients, recovery is incomplete, with prolonged amnesia regarding events that occurred close to the time of treatment. 44 Preexisting cognitive impairment is predictive of amnesia after ECT, and amnesia is more likely in older adults. 45 Variations in ECT technique (e.g., right unilateral electrode place ment or ultrabrief pulse width) can reduce the incidence and severity of retrograde amnesia sub stantially. 46,47 For example, persistent loss of auto biographical memories 2 months after treatment is greater with bilateral than with right unilat eral ECT. 43 Other side effects of ECT include headache, muscle aches, nausea, and fatigue. Despite con cerns about structural brain injury with ECT, stud ies in both humans and nonhuman primates have not shown evidence of anatomical damage. [48] [49] [50] [51] A R E A S OF UNCER TA IN T Y Perhaps the most pressing issue in the field of ECT is how to prevent relapse after a remission has been induced by a short course of treatment during an acute episode of depression. In one trial, patients who did not receive any form of maintenance therapy had a relapse rate of 84% 6 months after ECT. 52 Monotherapy with nortrip tyline reduced the relapse rate to 60%, and com bination therapy with nortriptyline and lithium reduced the relapse rate to 39%. 52 The CORE group found that 46% of patients with depression that remits after ECT remain well at 6 months when they receive maintenance treatment with either combination pharmacotherapy or mainte nance ECT. 53 In a report on ECT use in the com munity setting, only 36% of patients remained well, perhaps because of less aggressive mainte nance treatment or premature discontinuation of ECT in the presence of residual symptoms. 36 Another concern involves the burden of cog nitive side effects of ECT. In addition to changes in electrode placement, a shorter pulse width has been reported to reduce amnesia associated with ECT. 54 Other approaches have included improv ing the localization of seizure induction with the use of magnetic fields that can be targeted more precisely than electrical stimulation because of the absence of impedance. 55 Work to date with magnetic seizure therapy has been encouraging, but it is still in the research phase.
Other studies have examined the efficacy of alternatives to seizure induction for the treatment of depression. Electromagnetic treatments such as subconvulsive dosages of transcranial magnet ic stimulation have been used with encouraging results and an excellent safety profile, 56 but they are associated with a smaller effect size than that seen with ECT. Vagusnerve stimulation is ap proved by the Food and Drug Administration as an alternative for the adjunctive management of treatmentresistant depression. This treatment does not have known cognitive side effects and has shown some benefit in longterm manage ment, 57 but it does not have the speed of action or the large effect size of ECT.
GUIDEL INE S
The APA endorses ECT when it is administered by properly qualified psychiatrists for appropriately selected patients in accordance with the guide lines of the APA's Task Force on Electroconvul sive Therapy. 38 Most practice guidelines for de pression recommend ECT only for difficulttotreat depression, often as a fifth, sixth, or seventh step after the failure of other therapy. The APA also supports the use of ECT for relapse prevention. In the United Kingdom, the National Institute for Clinical Evidence recommends the restriction of ECT to patients with severe depression, catatonia, or prolonged or severe mania, and, unlike the APA, this organization does not recommend ECT as maintenance therapy. 58 The APA task force guidelines on ECT set forth detailed criteria for patient selection, medical screening, ECT procedures, and training in ECT. 38 ECT practitioners must be credentialed by their local hospital, but there is no nationwide quality assurance program or board certification for ECT practice in the United States. In other countries, more active approaches have been taken to moni tor and ensure quality in ECT centers. 59 R EC OM MENDAT IONS I would recommend ECT for the patient described in the vignette for several reasons. ECT would be appropriate given her lack of a response to or intolerance of adequate trials of antidepressant medications and neuroleptic agents. In addition, the presence of suicidal ideation with a plan for suicide underscores the need for a rapidly acting and definitive treatment. The presence of the psychotic subtype in this patient is a good prog nostic indicator for a response to ECT, as is her age. It would be appropriate to consider starting with right unilateral ECT at an adequate dosage above the seizure threshold, but if she does not have a response, bilateral ECT could be used. Giv en the severity of her depression and her history of multiple episodes, I would also recommend combining ECT with an antidepressant medica tion to prevent a relapse, tapering the ECT rather than abruptly discontinuing it on remission, and adding a mood stabilizer to the antidepressant to prevent a relapse. Maintenance ECT is also a rea sonable strategy, and it should be discussed with the patient and her family before the initiation of treatment.
